Gary Bakst, M.D.
Endocrinology, Diabetes & Metabolism Physician in Albany, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,852 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Gary Bakst, M.D. reported a CMS MIPS final score of 76.7/100 - below the 83.1 national average - and filed 8,939 Medicare Part D claims in 2023.
- 76.7/100
- MIPS score · -6 vs avg
- 9K
- Part D claims, 2023
- 52%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Gary Bakst, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
77 21st percentile higher than 21% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Gary Bakst, M.D. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,521 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Gary Bakst, M.D. writes more Part D claims than 95% of them and scores higher on MIPS quality than 26% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Gary Bakst, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Gary Bakst, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Gary Bakst, M.D.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New York
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among New York providers
Endocrinology, Diabetes & Metabolism Physician ranks #77 among New York's specialties (0.1% of in-state providers)
Each bar is a specialty's share of the New York provider total, by primary NUCC taxonomy. The highlighted bar is Endocrinology, Diabetes & Metabolism Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Gary Bakst, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 76.7/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) - 76.7/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
76.7/100 MIPS final score - 6.4 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Endocrinology, Diabetes & Metabolism Physician. Quality dim: 78. Cost dim: 61.
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Gary Bakst, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 1365 WASHINGTON AVE, Albany, NY, 12206, with a listed phone of (518) 489-4704. NPI 1275530537 was issued on 07/01/2005.
Medicare Part D records for calendar year 2023 show 8,939 prescription claims written by this provider, covering 1,050 Medicare beneficiaries and totaling roughly $4.9 million in drug spend, split 41% brand-name and 52% generic by claim count, with an opioid prescribing rate of 0.4%. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 76.7/100 for the 2023 performance year (Quality 78, Cost 61), compared with the national average of 83.1.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1275530537 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 07/01/2005 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Gary Bakst, M.D.'s current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
Profile fields combine the CMS NPPES monthly snapshot (provider directory, taxonomy, and address) with calendar-year 2023 Medicare Part D and MIPS public-use files when records are present. NPI 1275530537 is the unique 10-digit identifier CMS uses to link Bakst across every Medicare, Medicaid, and HIPAA-covered transaction. Read full methodology →
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Gary Bakst, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Gary Bakst, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$2.4K
Largest payer
Lilly USA, LLC
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Gary Bakst, M.D.. To verify Gary Bakst, M.D.'s current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
41% brand-name claims vs 52% generic, on 8,939 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 22,933
- Total Day Supply
- 682,124
- Brand vs Generic
- 41% brand / 52% generic
- Brand Drug Cost
- $4.6M
- Generic Drug Cost
- $183K
- Opioid Claims
- 36 (0.4% rate)
- Antibiotic Claims
- 56
Patient Demographics
- Average Patient Age
- 73.6 years
- Avg HCC Risk Score
- 1.23
- Gender Split
- 60% female / 40% male
- Age Distribution
- <65: 64, 65-74: 522, 75-84: 369, 85+: 95
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Gary Bakst, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
959 claims
- Ozempic
Ozempic
473 claims
- Synthroid
Synthroid
464 claims
- Metformin Hcl
Metformin Hcl
410 claims
- Atorvastatin Calcium 383
Atorvastatin Calcium
383 claims
- Jardiance 342
Jardiance
342 claims
- Trulicity 230
Trulicity
230 claims
- Novolog Flexpen 223
Novolog Flexpen
223 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 959 |
| Ozempic Semaglutide | 473 |
| Synthroid Levothyroxine Sodium | 464 |
| Metformin Hcl | 410 |
| Atorvastatin Calcium | 383 |
| Jardiance Empagliflozin | 342 |
| Trulicity Dulaglutide | 230 |
| Novolog Flexpen Insulin Aspart | 223 |
| Rosuvastatin Calcium | 210 |
| Metformin Hcl Er Metformin Hcl | 142 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How Gary Bakst, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
Gary Bakst, M.D.'s 8,939 claims are above the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Bakst.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the New York medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is Gary Bakst, M.D.'s specialty? ▼
How much does Gary Bakst, M.D. prescribe under Medicare Part D? ▼
What is Gary Bakst, M.D.'s Medicare quality score? ▼
Where is Gary Bakst, M.D. located? ▼
What is Gary Bakst, M.D.'s NPI number? ▼
Does Gary Bakst, M.D. prescribe more brand-name or generic drugs? ▼
Does Gary Bakst, M.D. prescribe opioids? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does Gary Bakst, M.D. prescribe most often? ▼
Does Gary Bakst, M.D. accept Medicare? ▼
How can I verify Gary Bakst, M.D.'s credentials? ▼
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology